the present constitutes a marked improvement in the area of injection of therapeutic materials into voids in tissue such as bone and / or implant devices such as bone screws , not only because it provides multiple functions in a single device , which both saves time and reduces the potential for error during surgery , but also because the interaction between the parts provides functionality not available if the components were implanted individually . noted advantages include : the plug material is maintained in a sleeve , namely the plug guide cannula , prior to and during implantation and may be pre - formed to be compatible with the standard trocar , drill bit , or bone screw bore sizes . this plug guide cannula , not only compresses the plug into the desired geometric configuration , but also serves as a channel and mating unit which engages the proximal opening to the void in the tissue or implant and guides the plug into such . additionally , the plug guide cannula serves a protective purpose while the device is in the sterile package and during handling in surgery ; in particular , the plug guide cannula protects against mechanical damage , and reduces exposure to open air which might result in excessive evaporation of liquid components of the plug or exposure to airborne contaminants . the needle transits the length of the plug prior to insertion in the body tissue ( or implanted device ), and the needle and plug may be assembled and inserted as a unit . if the needle is inserted after the plug is inserted , there is the potential for the needle to either not completely transit the plug or push the plug further into the tissue than desired ; plug material may also jam in the bore of the needle . the device provides a positive means to set both the plug depth and the needle tip depth in the tissue . the plug pusher holds the plug in place during the injection of therapeutic material , thereby allowing the surgeon to apply a force sufficient to overcome hydraulic resistance in the surrounding tissue , not only assuring delivery of the therapeutic , but also providing important tactile feedback to the surgeon . if the surgeon were just to inject through a plug , there is the potential for the plug to ‘ blow back ’. the plug pusher can hold the plug in place while the needle is being extracted ; otherwise friction between the needle and the plug might pull the plug part or all of the way out of the hole in the bone or bore of the screw . although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention , the preferred methods , devices , and materials are now described . however , before the present materials and methods are described , it is to be understood that the present invention is not limited to the particular sizes , shapes , dimensions , materials , methodologies , protocols , etc . described herein , as these may vary in accordance with routine experimentation and optimization . it is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only , and is not intended to limit the scope of the present invention which will be limited only by the appended claims . unless otherwise defined , all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs . however , in case of conflict , the present specification , including definitions , will control . the words “ a ”, “ an ” and “ the ” as used herein mean “ at least one ” unless otherwise specifically indicated . thus , for example , reference to a “ molecule ” is a reference to one or more molecules and equivalents thereof known to those skilled in the art , and so forth . the term “ proximal ” as used herein refers to that end or portion which is situated closest to the user of the device , farthest away from the target surgical site . the term “ distal ” as used herein refers to that end or portion situated farthest away from the user of the device , closest to the target surgical site . the term “ axial ” as used herein refers to the direction relating to or parallel with the longitudinal axis of the device . in the context of the present invention , the plug positioned within the bore of the plug guide cannula and may be axially ( distally ) moved therein and displaced therefrom by means of a plug pusher or plunger . the term “ lateral ”” as used herein refers to the direction relating to the transverse axis of the device . in the context of the present invention , the target site may be provided with a fenestrated surgical screw having a series of pores or fenestrations positioned about its lateral surface . the present invention is directed , at least in part , to the introduction and retention of therapeutic materials ( also referred to herein as remedial , beneficial and / or therapeutic agents ) through holes or voids in bodily tissue or through the bore of an implanted device . in the context of the present invention , the term “ therapeutic ”, “ therapeutic materials ” and “ remedial ”, “ beneficial ” and “ therapeutic ” “ agents ” refers to any material which is , or can be , injected through a hypodermic needle or other cannula device , into tissue with an intended effect which is advantageous to the health or well - being of the patient . of particular value in the context of the present invention are those agents with known benefit to the musculoskeletal system , such as , stem and precursor cells and other biological cells , bioactive cytokines ( particularly growth factors , bone morphogenetic protein , angiogenesis factors ), hormones , adipose extracts , anti - cancer drugs ( including chemo - therapy agents ), bone cements and mixtures comprising in part calcium bearing molecules , antibiotics and other anti - infection agents , blood thinning agents , analgesics , dna and combinations of any or all of the above . in the context of the present invention , bone marrow aspirate and compositions comprising such are of particular value . in the context of the present invention , the term “ stem cell ” represents a generic group of undifferentiated cells that possess the capacity for self - renewal while retaining varying potentials to form differentiated cells and tissues . stem cells can be totipotent , pluripotent or multipotent . derivative stem cells that have lost the ability to differentiate also occur and are termed ‘ nullipotent ’ stem cells . a totipotent stem cell is a cell that has the ability to form all the cells and tissues that are found in an intact organism , including the extra - embryonic tissues ( i . e . the placenta ). totipotent cells comprise the very early embryo ( 8 cells ) and have the ability to form an intact organism . a pluripotent stem cell is a cell that has the ability to form all tissues found in an intact organism although the pluripotent stem cell cannot form an intact organism . a multipotent cell has a restricted ability to form differentiated cells and tissues . typically adult stem cells are multipotent stem cells and are the precursor stem cells or lineage restricted stem cells that have the ability to form some cells or tissues and replenish senescing or damaged cells / tissues . further information may be found in wo 08 / 007082 , the contents of which are incorporated by reference herein . in the context of the present invention , the term “ progenitor cell ” refers to unipotent or multipotent cells , which comprise the stage of cell differentiation between stem cells and fully differentiated cells . in the context of the present invention , the term “ biological cell ” refers to any cell capable of performing useful biological functions in a living organism , particularly replication to form a tissue structure . the term as used herein includes stem cells , progenitor cells and fully differentiated cells . biological cells may include cells from the intended host organism or those from a donor organism . biological cells can include cells from recombinant or genetic engineering techniques . in the context of the present invention , the term “ bioactive molecules ” refers to any molecule which has the capacity to interact with a living tissue or system in such a way as to exhibit or induce a biological activity in an organism , tissue , organ or cell , either in vivo , in vitro or ex vivo . the term “ bioactive molecule ” extends to precursor forms thereof . precursor proteins , for example bmp precursors , are typically inactive until they undergo endoproteolytic cleavage ; however , in that this is a process that naturally occurs in the body , the present invention extends to precursor proteins that participate in useful biological processes in the body . of particular interest in the context of the present invention are bioactive peptides that trigger or regulate biological functions . illustrative examples of bioactive molecules suitable for use in the context of the present invention include , but are not limited to , are growth factor proteins , such as tgfβ , bmp - 2 , fgf and pdgf . in the context of the present invention , the term “ growth factors ” refers to the broad class of bioactive polypeptides which controlling and regulating a variety of endogenous biological and cellular processes , such as cell - cycle progression , cell differentiation , reproductive function , development , motility , adhesion , neuronal growth , bone morphogenesis , wound healing , immune surveillance and cell apoptosis . growth factors typically operate by binding to specific receptor sites on the surface of target cells . growth factors include , but are not limited to , cytokines , chemokines , polypeptide hormones and the receptor - binding antagonists thereof . examples of well known growth factors include but are not limited to : bone morphogenic protein ( bmp ); transforming growth factor beta ( tgf - β ); interleukin - 17 ; transforming growth factor alpha ( tgf - α ); cartilage oligomeric matrix protein ( comp ); cell density signaling factor ( cds ); connective tissue growth factor ( ctgf ); epidermal growth factor ( egf ); erythropoietin ( epo ); fibroblast growth factor ( fgf ); glial derived neurotrophic factors ( gdnf ); granulocyte - colony stimulating factor ( g - csf ); granulocyte - macrophage colony stimulating factor ( gm - csf ); growth differentiation factor ( gdf ); myostatin ( gdf - 8 ); hepatocyte growth factor ( hgf ]; insulin - like growth factor ( igf ); macrophage inhibitory cytokine - 1 ( mic - 1 ); placenta growth factor ( pigf ); platelet - derived growth factor ( pdgf ); thrombocyte concentrate ( prp ); thrombopoietin ( tpo ); vascular endothelial growth factor ( vegf ); activin and inhibin ; coagulogen ; follitropin ; gonadotropin and lutropin ; mullerian inhibiting substance ( mis ) also called : anti - müllerian hormone ( amh ) mullerian inhibiting factor ( mif ) and mullerian inhibiting hormone ( mih ); nodal and lefty ; and noggin therapeutic molecules which regulate , induce or participate in useful biological processes in the body , including those listed above , are often categorized or classified according to their particular structure or function . for example , immunoregulatory proteins secreted by cells of the immune system , such as interleukin and interferon , are often referred to as cytokines . other categories of regulatory molecules include , but are not limited to : morphogens ( e . g ., molecules that regulate or control the formation and differentiation of tissues and organs ); chemokines ( e . g ., any of a group of cytokines produced by various cells , as at sites of inflammation , that stimulate chemotaxis in white blood cells such as neutrophils and t cells ); hormones ( e . g ., a product of living cells that circulates in body fluids such as blood and produces a specific , often stimulatory effect on the activity of cells , usually remote from its point of origin ); receptors ( e . g ., a molecule present on a cell surface or in the cell interior that has an affinity for a specific chemical entity , including both endogenous substances such as hormones and ligands as well as foreign materials , such as viral particles , that serves as an intermediary between the stimulating agent and the downstream physiological or pharmacological response thereto ; receptor - binding agonists ( e . g ., a chemical substance capable of combining with a specific receptor on a cell and initiating the same reaction or activity typically produced by the endogenous binding substance ( such as a hormone ); and receptor - binding antagonists ( e . g ., a chemical substance that reduces the physiological activity of another chemical substance ( such as a hormone ) by combining with and blocking one or more receptors associated therewith ). however , since the study of the function of the various regulating moieties in the body is still an emerging science , the categorization thereof is also evolving . accordingly , the present invention is not limited to any one particular class or category of regulating or stimulating molecules . as used herein , the term “ growth factors ” also refers to precursor forms of growth factors , which are typically inactive until they undergo endoproteolytic cleavage , as well as synthesized and recombinant forms which provide part or all of the same or similar functions as the naturally occurring growth factors . accordingly , the present invention encompasses precursors , analogues , and functional equivalents of growth factors , provided the resulting molecules retain some or all of the function of regulating useful biological processes in the body , typically by binding to specific receptor sites on the surface of target cells associated with the wild - type or endogenous moiety . the term “ therapeutic agents ” as used herein refers to any molecule , compound or composition having therapeutic potential , more particularly pharmaceutical activity . examples of particularly useful therapeutic and / or pharmaceutical activities include but are not limited to anti - coagulation activity , anti - adhesive activity , anti - microbial activity , anti - proliferative activity , and biomimetic activity . in the context of the present invention , the term “ therapeutic materials ” refers to any composition which comprises any of the following : therapeutic agents , bioactive molecules , stem cells , progenitor cells or biological cells . the term “ bioactive solution ” refers to a liquid composition which comprises , in part , bioactive materials . in the context of the present invention , the term “ antimicrobial ” refers to any molecule which has the capacity to limit or interfere with the biological function of a bacterial , fungal or viral pathogen or a toxin . antimicrobial is intended to also encompass antibacterial , antibiotics , antiseptics , disinfectants and combinations thereof . as used herein , the term “ tissue ” refers to biological tissues , generally defined as a collection of interconnected cells that perform a similar function within an organism . four basic types of tissue are found in the bodies of all animals , including the human body and lower multicellular organisms such as insects , including epithelium , connective tissue , muscle tissue , and nervous tissue , and additional specialized tissue , such as teeth . these tissues make up all the organs , structures and other body contents . as used herein , the term “ bone ” refers to the rigid organs that form part of the endoskeleton of vertebrates and function to move , support , and protect the various organs of the body , produce red and white blood cells and store minerals . one of the types of tissues that make up bone is the mineralized osseous tissue , also called bone tissue , which gives it rigidity and honeycomb - like three - dimensional internal structure . other types of tissue found in bones include marrow , endosteum , and periosteum , nerves , blood vessels and cartilage . cartilage is a type of dense connective tissue composed of collagen fibers and / or elastin fibers that can supply smooth surfaces for the movement of articulating bones . cartilage is found in many places in the body including the joints , the rib cage , the ear , the nose , the bronchial tubes and the intervertebral discs . there are three main types of cartilage : elastic , hyaline , and fibrocartilage . accordingly , the term “ tissue ” as used herein broadly encompasses all biological components including , but not limited to , skin , muscle , nerves , blood , bone , cartilage , teeth , tendons , ligaments , and organs composed of or containing same , as well as derivatives thereof , such as demineralized bone matrix . while the constructs and assemblies of the present invention have particular applicability to bone treatment , the present invention is not limited thereto . rather , the teachings of the present invention may be applied to other analogous situations , in connection with other tissues and organs . in the context of the present invention , the term “ plug ” or “ plug material ” refers to any solid , semi - solid , or gel material , or combinations thereof , which when implanted in tissue or the bore of a cannulated implant device , such as a bone screw , provides a full or partial hydraulic barrier to flow from one side of the plug along the linear axis of the hole or bore to the other side . additionally , said plug material can include one or more liquid components . typical materials are bio - compatible . typically , in the case of plugs inserted into non - elastic ( or less - elastic ) implants or tissue , said plug is comprised , at least in part , of elastomeric or otherwise deformable or shapeable materials . alternatively , the use of a non - deformable plug material combined with a deformable coating , including , but not limited to , an adhesive is contemplated by the present invention . plugs inserted into more - elastic implants or tissues ( i . e ., those that are themselves deformable ) may be fabricated from either non - deformable or deformable materials or a combination thereof . illustrative plug materials include , but are not limited to : polymer solids , foams , films and fibers , with particular value in biodegradable polymers , such as polylactic acid ( pla ) and poly - lactic - co - glycolic acid ( plga ), biological solids , foams and fibers , such as collagen , bone matrix and bone products treated to exhibit properties , such as elastic or other properties , bone putty , gel and cement and the range of calcium based compounds known to those skilled in the art , adipose tissue , other biological tissue , including autogenic and allogenic tendon and ligament tissue . additionally , the plug can also comprise balloon - type constructs and highly viscous materials . additional components to imbue specific properties to the plug are also of value , such as , but not limited to the use of fibrin glue and related materials to increase the adhesion between the plug and the wall of the hole in the tissue or bore of the implant device . bone void fillers , such as collagen mixed with calcium phosphate salt or other calcium molecule bearing compounds , or collagen mixed with demineralized bone matrix are readily available and are of value as plug materials in the context of the present invention . of particular interest in the context of the present invention are materials and mixtures which expand through absorption of water or other materials , such as mixtures comprising , in part , hydrophilic materials which form hydrogels , or materials , such as sponge - like materials , which are maintained in a compressed state by a material with water soluble bonds are of particular interest . plug materials which under go a state change through change in temperature , such as a bone wax which can transition from a liquid or semi - liquid state to a more solid state once implanted at body temperature are of value . plug materials which undergo a reactive or solvent based transition to a more solid state are also of interest , such as epoxies , or other cements known to those skilled in the art . plug materials which comprise different materials in different areas of the plug are of particular interest in the context of the present invention ; a plug wherein the walls of the plug have an effective concentration of material which provides increased friction between the plug and the walls of the hole in the bone or bore of the implant device , such as fibronectin based molecules , is of value ; as previously mentioned a core of the plug which is expansive in nature and increases the radial force of plug against wall is of value ; a material at the proximal end of the plug which abuts to the distal end of the plug pusher which exhibits a low level of binding between the two , such as fibrous polymer , is of value ; and other configurations , which might be envisioned by one skilled in the art to achieve the desired effects described herein . in the context of the present invention , a flow barrier is anything that restricts or impedes , at least in part , the movement of material from one area to another . typically this is a result of reduction in the open area available for the flow of material . accordingly , plug materials can present either a complete barrier to flow , such as with a wax plug which occupies all the cross - sectional space , or a partial barrier to flow , such as might be envisioned with a fibrous filter material . in either context , a substantial reduction in fluid flow across the opening is achieved . in the context of the present invention , in addition to serving as a proximal flow barrier , the plug of the present invention can also be used to itself deliver , either as a bolus or over an extended period of time , a therapeutic material which is identical to or separate from the therapeutic material which is injected ; for example , there might be advantages to the plug containing anti - infectious agents . the therapeutic agents which may be contained ( e . g ., adsorbed ) within and dispensed from , preferably over an extended period of time , the material of the plug are analogous to those which may be injected across the plug , via the hypodermic needle , and include those mentioned above . specifically preferred examples include , but are not limited to , growth factors and other cytokines , stem and progenitor cells , antibiotics , chemotherapeutics and other cancer drugs , imaging compounds , analgesics , and the like as well as combinations thereof . in the context of the present invention , the “ core device ”, “ flow tube ”, hypodermic needle or other cannulated fluid delivery tube can comprise any fluid portal which can provide a hydraulic path between the proximal side of the plug and the distal side of the plug . the length and gauge of the needle required will vary with the length of the assembled device , the diameter of the hole being injected into and the propensity of the therapeutic material to plug . of particular value in the context of the present invention is a hypodermic needle with a luer - lock - type fitting , such as might be found with a spinal needle ; this type of needle typically has an extended length which makes it of value in transiting the length of the assembled device . in the context of the present invention , the cannulated flow tube can be of any material which is compatible with being provided in a sterile state and does not adversely react with any other component in the system or the body tissue . stainless steel is in common use for hypodermic needles and is well - suited to the device of the present invention . polymer tubes , both rigid and flexible are also of value in the present invention . a collapsible tube which only passes fluid when sufficient pressure is introduced at one end is also of value in the present invention , and it should be noted that in such a case , the tube may not have to be removed from the plug after injection of the therapeutic material . the connection of the needle or tube to the therapeutic fluid reservoir and the fluid reservoir itself can be of any form readily envisioned by one skilled in the art ; in the context of the present invention , a syringe with luer - lock - type connection is preferred because of the prevalence of these devices on the market . the “ plunger ” or “ plug pusher ” of the present invention may be fabricated from any material having the requisite structural integrity to transit force applied by the surgeon to insert the plug into the hole or bore and maintain the plug in that position during injection of the therapeutic material . typically , the proximal end ( end away from the patient ) will have some form of protuberance to afford the surgeon leverage in pushing the plug into the tissue and holding it there during injection and during the process of extracting the hypodermic needle . in the case of a luer - lock - type or other twist type connect on the needle , the plug pusher may , but is not required to , have a design which restricts the ability of the needle to rotate around the linear axis in relation to the plug pusher . additionally , the plug pusher may , but is not required to , have a positive restraint to maintain the needle in the plug pusher until the surgeon wishes to remove it ; said restraint can consist of a removable clip , or any other restraint as might be envisioned by one skilled in the art . typically , the shaft of the plug pusher will have some type of indicia or mark ( s ) along the length of the shaft which are covered up by the plug guide cannula as the plug pusher is pushed into the plug guide to displace the plug into the tissue or implant device . the covering up of this mark ( or marks ) will provide the surgical personnel with a visible indication of the depth of insertion of the plug . in the context of the present invention , the plug guide ( also referred to herein as a plug guide cannula , channel , tube or sleeve ) comprises a tube - like structure which constrains the plug in a configuration compatible with insertion into a void of predetermined diameter , protects the plug prior to insertion , engages with the opening of the hole or bore in a manner which is conducive to the transfer of the plug from the plug guide into the hole , provides a positive stop to insure the relative position of the plug guide and the tissue or the cannulated implant device , provides a limiting stop for the plug pusher . the plug guide cannula may also comprise a specialized distal end to mate with bone or implant device in a specific manner , for example , the exterior wall of the plug guide cannula may have a hexagonal cross - section to mate securely with the head of a hex - drive bone screw . the plug guide cannula may also comprise at the proximal end protuberances to facilitate handling by the surgeon , or to provide a limiting stop in the case where the plug guide is being inserted into a surgical cannula that has been used as a guide for forming a hole in tissue or bone . the plug guide cannula may also have incorporated in the proximal end a positive stop to prohibit the plug guide from being pulled off of the plug pusher ; this can be accomplished by tabs on the plug guide which run in a groves along a portion of the length of the plug pusher , or through other means readily envisioned by one skilled in the art . the plug guide cannula can comprise any material or combination of materials that provide the requisite structural integrity and are compatible with other components of the system and medical use . of particular interest in the context of the present invention are low - friction polymers that can be sterilized , such as certain grades of nylon , which have are slightly elastic such that they provide a tight fit to the plug pusher . in some instances , a straight metallic sleeve or a metallic sleeve with a polymer lining may be preferred over a straight flexible polymer sleeve for structural reasons , particularly when dealing with hole diameters less than 2 millimeters . in certain instances , it may be advantages to advance the plug through a surgical cannula which is of a size which is compatible with the opening in the tissue . this is often the case when a trocar / cannula combination has been used to create the hole in bone . in this case , the surgical cannula of the trocar / cannula combination may be used as the plug guide cannula . the device of the present invention will include a plug guide cannula , or in this case a “ plug holder ” which mates with the proximal end of the surgical cannula and permits transfer of the plug to the surgical cannula , such that the plug pusher pushes the plug through the surgical cannula and into the bone or implant device . the present invention is particularly useful for introducing therapeutic materials into the bore of a surgical implant , such as a bone screw . however , the invention is not limited to osteoimplants . it not only finds utility in connection with other type of implants or prosthetic devices but also finds utility in connection with bones or tissue alone , in the absence of such implants . accordingly , the device and assembly of the present invention may used to introduce therapeutic materials into voids in tissue or bone through openings that are natural , disease - associated or surgically introduced . for example , the device and assembly of the present invention may used to deliver useful material to areas of necrotic or cancerous bone . in addition to serving as a means for delivering therapeutic materials , the constructs of the present invention also find utility in the aspiration or removal of material from a hole or void in a tissue or bone , for example , aspirating bone marrow from the hip bone or aspirating excess fluid from an arthritic joint . the constructs of the present invention also have spinal column applications as well as potential utility in connection with soft organs and tissues . hereinafter , the present invention is described in more detail by reference to the figures and examples . however , the following materials , methods , figures , and examples only illustrate aspects of the invention and are in no way intended to limit the scope of the present invention . for example , while the present invention makes specific reference to orthopedic bone screws , it is readily apparent that the present invention has other applications , such as those mentioned herein . as such , methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention . surgical treatment is provided for a patient with chronic degenerative insertional tendinopathy with thickening fibrosis and tearing of the achilles tendon from the calcaneus extending approximately 5 - 6 cm , who has failed conservative treatment . in surgery , the peritinon is incised , the tendon is debrided and all non - viable tendon is removed , the diseased portion of the calcaneus is resected , and the flexor hallucis longus ( fhl ) tendon is approached . a section of the fhl tendon is harvested and formed into a 5 mmø × 3 mm plug and inserted and securely packed into a plug guide cannula of the present invention by trained personnel . a 2 mmø guide wire is driven into the calcaneus at the desired point of reattachment of the tendon . a 5 mmø cannulated drill is then used over the guide wire to create the attachment tunnel . the free end of the portion of fhl tendon which remains attached to muscle is sutured and passed through the tunnel and appropriately tensioned before a 5 . 5 mmø × 3 mm pla / plga interference screw is inserted in the tunnel to secure the tendon . a syringe with 4 cc of autologous bone marrow aspirate concentrate is attached by means of a luer - lock fitting to the needle of the device of the present invention , and the syringe is depressed sufficiently to clear the needle of entrapped air . the device is then positioned at the head of the interference screw and the plug and needle assembly is displaced into the screw according to the method of the present invention . the bone marrow aspirate is then injected into the region of the screw at the distal side of the plug . the needle is removed while the plug pusher is held in place , and then the plug pusher and plug guide assembly is removed . surgical treatment is provided for a patient with an osteopenia and intertrochanteric femur fracture . the fracture is reduced and a hip screw and plate device is surgically inserted and affixed using 4 . 5 mmø × 4 cm cannulated titanium screws . in the process of screw placement , the screws are driven to a point representing 75 % of the final insertion depth . at that point , a device of the present invention is utilized in conjunction with the screw . the device comprises , in part , a calcium putty plug , and has attached to the needle , a reservoir of methyl - methacrylate bone cement . the device is abutted to the partially inserted screw ; the plug pusher is displaced into the plug guide cannula to a point where the plug and the needle tip are displaced into the target screw . the bone cement is then injected into the screw . the needle is removed , and then the plug pusher is removed . the screw is then driven the remaining portion to full depth and , in this process , the driving bit provides the additional benefit of holding the plug in place in the screw during the process of driving the screw further into the bone . a patient with avascular necrosis of the femoral head prior to the onset of subchondral fracture undergoes a procedure for structural decompression that involves core drilling , flushing of the affected zone with a solution thought to halt osteoclastic breakdown ( in cases of suspected infection , an antibiotic treatment may be added or substituted ), and then treatment of the area with cellular therapy through the insertion of mesenchymal stem cells ( msc ) in a autologous plasma matrix which also contains therapeutic levels of platelet - derived growth factor ( pdgf ). this is accomplished through the following procedure : ( a ) an incision is made to access the trochanteric section of femur . ( b ) a 6 . 5 mmø outside × 60 mm surgical cannula is introduced into the incision and placed on the bone as a guide . ( c ) a 5 mm drill is introduced into the cannula and under image guidance the affected area is penetrated by a plurality of holes originating from the single cannula access point using a fanning technique . ( d ) a construct of the present invention is introduced into the cannula , the construct comprising : i . a plug guide cannula with a 5 mm inside diameter and an outside diameter less than the said surgical cannula , and a straight - wall length of 60 mm with a limiting protrusion on the proximal end to constrain insertion in the surgical cannula beyond 60 mm , ii . a 7 mm long plug of collagen sponge ( also foam ) compressed to 5 mm diameter , iii . a plug pusher , 5 mm in diameter and 63 mm straight wall length ; the plug pusher has a two 18 gauge needles with flexible shafts mounted within the plug guide cannula and eccentrically on opposite sides of the plug . ( e ) the surgical cannula is put at an angle to the surface of the bone , and one of the two needles is slid under imaging system guidance into the drill hole at one extreme of the fan pattern to an extent where it extends into an area of necrosis ; the surgical cannula is then reoriented to a different angle such that the second needle can be slid under imaging system guidance into a hole at the other extreme of the fan pattern . ( f ) the plug pusher is displaced into the plug guide cannula in a manner where the plug enters and seals the drilled entrance hole in the bone which is the focal point of the fan pattern of drill holes . ( g ) one needle is attached to a reservoir of an osteoclastic breakdown inhibitor solution and the second to a drain reservoir , and 1 cc / sec of solution is pumped through the area of necrosis for a 10 minute period . ( h ) the inhibitor ( or alternatively , antimicrobial ) solution reservoir is disconnected and the msc / pdgf solution is then introduced into the same needle until either the supply of msc / pdgf solution is exhausted or there is evidence of the same in the needle to the drain . ( i ) the needles are removed from the plug pusher / plug guide cannula assembly , and then the assembly is removed from the surgical cannula . the present invention provides a means for introducing and retaining a broad range of therapeutic cells , particularly stem cells , and other biologically significant and / or bioactive molecules in cannulated implants as well as in surgical holes in bone , cartilage , teeth and other tissue . applicable procedures that would benefit from the devices and assemblies of the present invention are common in orthopedic surgery , including spinal surgery , and dentistry . the present invention provides the surgeon with tools and devices which are compatible with existing surgical techniques and permits a more focused delivery of often expensive therapeutic materials . the present invention has particular value in the introduction of stem and other precursor cells , bioactive cytokines , including but not limited to growth factors as well as to the introduction of anti - cancer drugs , particularly those having a toxic effect and for which restricted application is desired . the devices , constructs , assemblies and methods presented herein provide for increased efficiency of operation in a surgical operating room environment with reduced potential for error . the devices , constructs , assemblies and methods also may result in fewer avenues of potential bacterial infections during surgeries . the efficiencies derived from the methods of the present invention can reduce the time in surgery , which , in turn , can reduce the stress on the patient &# 39 ; s body and has the potential to reduce the cost of the surgical procedure . the ability to efficiently introduce and retain therapeutic materials may result in a faster recovery from a medical condition . the disclosure of each publication , patent or patent application mentioned in this specification is specifically incorporated by reference herein in its entirety . however , nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention . while the invention is herein described in detail and with reference to specific embodiments thereof , it is to be understood that the foregoing description is exemplary and explanatory in nature and is intended to illustrate the invention and its preferred embodiments . through routine experimentation , one skilled in the art will readily recognize that various changes and modifications can be made therein without departing from the spirit and scope of the invention , the metes and bounds of which are defined by the appended claims .
described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine . the devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations , particularly those associated with voids in bone and tissue . one particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use , for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area . additionally , the present invention provides unique devices and methods for surgical introduction of such constructs . the present invention finds particular application in connection with introduction of stem and progenitor cells , bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants , such as bone screws and pins . the present invention also has beneficial use in the delivery of cancer drugs , antimicrobials , bone cements and other therapeutic materials .